Shionogi Looks Beyond Crestor to HIV Platform
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Shionogi still has a few years to reap the benefits of Crestor royalties from AstraZeneca, but the looming generic substitution of rival Lipitor is forcing the company to prepare for a slowdown of its blockbuster drug. But according to Macquarie Equities Research, revised ex-U.S. Crestor prospects, strong pipeline prospects and recent launches could position Shionogi well in the near term
You may also be interested in...
Green Cross Obtains South Korean Approval For Peramivir During Drive To Secure More Anti-Influenza Medicines Beyond Roche and GSK Products
SEOUL - South Korea's Green Cross has obtained approval from South Korea's FDA to sell the injectable antiviral drug Rapiacta (peramivir), developed by BioCryst Pharmaceuticals in the U.S., during a government drive to make more flu-fighting medicines available beyond Roche's Tamiflu (oseltamivir) and GlaxoSmithKline's Relenza (zanamivir)
Green Cross Obtains South Korean Approval For Peramivir During Drive To Secure More Anti-Influenza Medicines Beyond Roche and GSK Products
SEOUL - South Korea's Green Cross has obtained approval from South Korea's FDA to sell the injectable antiviral drug Rapiacta (peramivir), developed by BioCryst Pharmaceuticals in the U.S., during a government drive to make more flu-fighting medicines available beyond Roche's Tamiflu (oseltamivir) and GlaxoSmithKline's Relenza (zanamivir)
Green Cross Obtains South Korean Approval For BioCryst Influenza Therapy Peramivir
The deal is part of a drive to secure anti-influenza options beyond Roche and GSK products in preparation for the next round of global influenza.